Request for Continued Stay in Court Proceedings Submitted in Amarin First Amendment Litigation

Request for Continued Stay in Court Proceedings Submitted in Amarin First Amendment Litigation
Settlement Discussions Continue While Prior Court Ruling Remains in Effect

BEDMINSTER, NJ and DUBLIN, IRELAND  -- (Marketwired) -- 02/17/16 -- Amarin Corporation plc (NASDAQ: AMRN), announced today that parties to the Amarin First Amendment litigation have jointly requested a continued stay in court proceedings. Following the August 7, 2015 preliminary relief order granted in favor of Amarin and the physician plaintiffs, the Court was notified that the parties had conferred and agreed to explore the possibility of settlement. As settlement discussions remain ongoing, the parties have requested that further court proceedings be stayed until March 18, 2016. At or before that time, the parties will again file a letter advising the Court of any updates with regard to next steps.

The August 7th declaratory judgment that confirmed Amarin may engage in truthful and non-misleading speech promoting the off-label use of Vascepa remains in effect.

About Amarin

Amarin Corporation plc is a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health. Amarin's product development program leverages its extensive experience in lipid science and the potential therapeutic benefits of polyunsaturated fatty acids. Amarin's clinical program includes commitment to an ongoing outcomes study. Vascepa® (icosapent ethyl), Amarin's first FDA approved product, is a highly-pure, EPA-only, omega-3 fatty acid product available by prescription. For more information about Vascepa visit For more information about Amarin visit

Availability of other information about Amarin

Investors and others should note that we communicate with our investors and the public using our company website (, our investor relations website (, including but not limited to investor presentations and investor FAQs, Securities and Exchange Commission filings, press releases, public conference calls and webcasts. The information that we post on these channels and websites could be deemed to be material information. As a result, we encourage investors, the media, and others interested in Amarin to review the information that we post on these channels, including our investor relations website, on a regular basis. This list of channels may be updated from time to time on our investor relations website and may include social media channels. The contents of our website or these channels, or any other website that may be accessed from our website or these channels, shall not be deemed incorporated by reference in any filing under the Securities Act of 1933.

Amarin contact information: 

Investor Relations 

Kathryn McNeil 
Executive Director, Investor Relations 
Amarin Corporation plc
In U.S.: +1 (908) 719-1315
[email protected]

Graham Morrell
Trout Group 
In U.S.: +1 (646) 378-2954
[email protected]

Media Inquiries

Kristie Kuhl
Finn Partners
In U.S.: +1 (212) 583-2791
[email protected]

Source: Amarin Corp. Plc